Clinical trial NCT05432856: Impact of Metabolic Health Patterns and Breast Cancer Over Time in Women
Official title: Impact of Metabolic Health Patterns and Breast Cancer Over Time in Women
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cardiovascular Diseases
Cardiovascular Morbidity
Metabolic Disease
Lead sponsor: University of Alberta
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2022-06-27
Enrollment: 65
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Background \& Rationale:

Breast cancer (BC) is the most commonly diagnosed malignancy in women worldwide (2.1 million diagnoses in 2018, 25% of new cancer cases). In Canada, early stage BC mortality rates have decreased by 48% over the past 30 years as a result of advances in prevention, detection, and treatment. However, competing risks for mortality from non-cancer causes have emerged, where cardiovascular disease (CVD) is now a leading cause of death for BC survivors. The direct toxic effects of BC treatment on the heart (cardiotoxicity) are well characterized by the investigators and many others, as a contributor to elevated cardiovascular risk. However, BC treatment and the associated lifestyle changes (i.e. physical inactivity, poor diet quality, stress) are increasingly recognized to also strongly affect metabolism negatively manifesting as insulin resistance, dyslipidemia and adipose tissue (fat) accumulation. These adverse metabolic changes are strongly linked to CVD risk and represent a currently underappreciated contributor to the elevated CVD risk among BC survivors. Preliminary data and recent publications demonstrate that regional fat accumulation occurs during BC treatment and that the fat burden in key locations is associated with poor cardiorespiratory health. A trigger of these adverse metabolic and inflammatory effects is excess fat specifically within ectopic fat (viscera, intermuscular, or hepatic) regions. In 2019, a member of the study team found that the volume of visceral and intermuscular but not subcutaneous fat at BC diagnosis were linearly associated with CVD events within 6 years, even among those with normal BMI and after adjustment for pre-existing CVD risk factors and for BC treatment type. Using MRI, investigators found that \~1 year after chemotherapy, BC survivors had significantly larger depots of visceral fat (49% larger) and thigh intermuscular fat (41% larger) compared to age and sex-matched controls, despite similar BMI and subcutaneous fat volumes in the two groups. Investigators also showed that the fat fraction within the thigh muscle and visceral fat volumes independently explained \~50% of the variation in cardiorespiratory fitness (measured by peak VO2). In particular, peak VO2 is one of the most powerful predictors of all-cause and CVD mortality and health care costs, and is the most consistently reported negative sequelae after treatment for BC. Unfortunately, there are no known therapies to recover long-term myocardial damage (i.e. cell death, fibrosis) from cancer therapies. There are several reasons to target fat as a therapeutic target in BC patients: 1) The study team have compelling preliminary data showing accelerated formation of ectopic fat during BC treatment. 2) Investigator's recent data showed that high fat content in key fat pools was associated with reduced peak VO2. 3) The burden of fat and the associated metabolic abnormalities are dynamic and malleable, and thus highly treatable.

Research Question \& Objectives:

The primary purpose of this study is to evaluate the effect of a behavioural intervention involving supported time-restricted eating (TRE), diet quality improvements, and reduced sedentary time versus usual cancer and nutrition care in BC patients receiving chemotherapy treatment on ectopic fat, cardiometabolic profile, and chemotherapy outcomes. The investigators hypothesize that the intervention will attenuate the growth of ectopic fat during chemotherapy and reduce chemotherapy symptoms.


Eligibility criteria: Inclusion Criteria:

* Female biological sex at birth
* \>18 years
* Diagnosis of stage I, II, or III breast cancer
* starting neoadjuvant or adjuvant intravenous chemotherapy
* ECOG \<3;
* Oncologist approval to participate;
* English speaking (all study materials and study staff will be in English)
* Willing and able to adhere to study intervention

Exclusion Criteria:

* Individuals who do not have access to a smart phone with Bluetooth capability (required for Fitbit and for responding to intervention text messages) or at least a shared cell phone with someone in the same household (i.e., some couples may share a phone).
* Type 1 or type 2 diabetes who require exogenous insulin (due to the potential need to adjust insulin dosing with TRE) or with hemoglobin A1c \>10%
* Research MRI contraindications (e.g., pacemaker, magnetic implants, pregnancy)
* Uncontrolled thyroid disorder
* Self-reported eating disorder history
* Body mass index \<18.5 kg/m2 or clinical signs of cachexia (discretion of treating oncologist)
* ≥5% body weight loss within last 6 months
* Those who are currently working night/rotating shifts, eating within ≤10-hour window or consistently eating less than 3 meals/day in the past 3 months.
* patients who meet the criteria for medical clearance prior to exercise using the Physical Activity Readiness Questionnaire+ and are not cleared by their treating oncologist or family physician to perform maximal exercise testing.

Primary outcomes:
measure: Change in Fat Volumes
timeFrame: Baseline, 24-weeks, and 2 years
Secondary outcomes:
measure: Change in Thigh Fat Pool Volume
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Liver Fat Volume
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Subcutaneous Abdominal Fat Volume
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Metabolic Syndrome Z-score
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Framingham risk score
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Peak VO2
timeFrame: Baseline, 24-weeks, and 2 years
Other outcomes:
measure: Change in Insulin Resistance
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Waist to Hip ratio
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Resting Blood Pressure
timeFrame: Baseline, 24-weeks, and 2 years
measure: Change in Hormonal Markers
timeFrame: Baseline, 24-weeks, and 2 years
measure: Medical Outcomes
timeFrame: Up to 10 years after study completion
measure: Change in Cytokines
timeFrame: Baseline, 24-weeks, and 2 years
measure: Physical Activity
timeFrame: through study completion, an average of 2 years
measure: Dietary Intake
timeFrame: Up to 24 weeks
measure: Smoking Status
timeFrame: Baseline
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
city: Toronto
country: Canada
facility: University of Toronto
state: Ontario
Study officials:
affiliation: University of Alberta
name: Richard Thompson, PhD
role: PRINCIPAL_INVESTIGATOR
References: